AVBP - NASDAQ

ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma, Inc. Common Stock

AVBPยทNASDAQ

$29.78

-0.47%
HealthcareBiotechnology

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.39B
EPS-4.3200
P/E Ratio-6.89
Earnings Date08/10/2026
ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma, Inc. Common Stock Fair Value Envelope

AVBP ยท NASDAQ

Our analysis suggests that AVBP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $29.78, this represents a potential HIDDEN relative to our calculated worth for ArriVent BioPharma, Inc. Common Stock.

HIDDEN
Intrinsic Value
Current Price: $29.78

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$138.4M
+ Cash & Equivalents$45.5M
Firm Value-$92.8M
- Debt$14.0K
Equity Value-$92.8M
/ Shares Outstanding40,568,943B
DCF Value-$2
OVERVALUED BY 108%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$80.3M
-$40.1M
-$20.1M
-$10.0M
-$5.0M
-$2.5M
-$1.3M
-$627.3K
-$313.6K
-$156.8K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$80.3M
-$40.1M
-$20.1M
-$10.0M
-$5.0M
-$2.5M
-$1.3M
-$627.3K
-$313.6K
-$156.8K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$74.3M
-$34.4M
-$15.9M
-$7.4M
-$3.4M
-$1.6M
-$732.0K
-$338.9K
-$156.9K
-$72.6K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your AVBP research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.